X4 Pharmaceuticals, Inc. 8-K Summary
Business Context and Reporting Period
X4 Pharmaceuticals, Inc. (XFOR) filed this Current Report on Form 8-K on January 25, 2022. The Company is an emerging growth company incorporated in Delaware. This filing provides preliminary, unaudited financial data as of December 31, 2021, and updates regarding corporate presentations and clinical development pipelines.
Key Financial Metrics
The following preliminary estimates are provided for the period ended December 31, 2021. The filing does not provide data on revenue, profit, cash flow, or margins.
| Metric | Value |
|---|---|
| Cash, Cash Equivalents, and Restricted Cash | Approximately $83.0 million |
| Principal Amount of Outstanding Debt | $32.5 million |
| Common Stock Outstanding | 28,127,657 shares |
| Class A Warrants Outstanding | 3,886,154 shares (Exercise Price: $13.20) |
| Class B Warrants Outstanding | 5,416,667 shares (Exercise Price: $3.65) |
| Pre-funded Warrants ($0.001) | 1,750,000 shares |
| Pre-funded Warrants ($0.01) | 2,058,032 shares |
Material Changes
The filing does not provide comparative data for prior periods to determine material changes in financial metrics. The Company notes that actual consolidated balances may differ from these estimates upon completion of year-end closing and auditing procedures.
Outlook, Risks, and Unusual Items
- Unaudited Data: The financial figures presented are preliminary and unaudited. The audit for the year ended December 31, 2021, is ongoing.
- Corporate Updates: On January 25, 2022, the Company posted an updated corporate presentation and updated its clinical development pipeline chart (Exhibit 99.1).
- Legal Disclaimer: Information in Item 2.02 is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the final audited cash balance and debt principal in the upcoming 10-K filing, as current figures are preliminary estimates.
- Review the updated clinical development pipeline chart (Exhibit 99.1) for changes in drug development status.
- Monitor the Company's website for the updated corporate presentation referenced in Item 7.01.
- Confirm the final count of outstanding shares and warrants once the year-end audit is complete.